Answers are grounded in this paper and cite their sources.
Lymphoblastic lymphoma is the second most common type of non-Hodgkin lymphoma in children. Although outcomes are favorable after first-line therapy based on treatment regimens for acute lymphoblastic leukemia, the prognosis of patients with recurrent or refractory disease remains extremely poor, with overall survival rates of only about 50%. This article presents an analysis of factors contributing to resistance to therapy and highlights current strategies for the treatment of relapsed/refractory lymphoblastic lymphoma.
No takes yet. Share an insight, caveat, or question.
Romanenko et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: